373 related articles for article (PubMed ID: 24330529)
1. Serious Non-AIDS events: Immunopathogenesis and interventional strategies.
Hsu DC; Sereti I; Ananworanich J
AIDS Res Ther; 2013 Dec; 10(1):29. PubMed ID: 24330529
[TBL] [Abstract][Full Text] [Related]
2. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.
Hsu DC; Sereti I
Drugs; 2016 Apr; 76(5):533-49. PubMed ID: 26915027
[TBL] [Abstract][Full Text] [Related]
3. Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People.
Sunil M; Nigalye M; Somasunderam A; Martinez ML; Yu X; Arduino RC; Utay NS; Bell TK
AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1205-1209. PubMed ID: 27344921
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S;
PLoS One; 2015; 10(10):e0139981. PubMed ID: 26465293
[TBL] [Abstract][Full Text] [Related]
5. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.
Elvstam O; Marrone G; Medstrand P; Treutiger CJ; Sönnerborg A; Gisslén M; Björkman P
Clin Infect Dis; 2021 Jun; 72(12):2079-2086. PubMed ID: 32271361
[TBL] [Abstract][Full Text] [Related]
6. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART.
Zicari S; Sessa L; Cotugno N; Ruggiero A; Morrocchi E; Concato C; Rocca S; Zangari P; Manno EC; Palma P
Viruses; 2019 Feb; 11(3):. PubMed ID: 30818749
[TBL] [Abstract][Full Text] [Related]
7. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Dana T; Grusing S; Bougatsos C
JAMA; 2019 Jun; 321(23):2337-2348. PubMed ID: 31184705
[TBL] [Abstract][Full Text] [Related]
8. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
Lewden C; Salmon D; Morlat P; Bévilacqua S; Jougla E; Bonnet F; Héripret L; Costagliola D; May T; Chêne G;
Int J Epidemiol; 2005 Feb; 34(1):121-30. PubMed ID: 15561752
[TBL] [Abstract][Full Text] [Related]
9. HIV and inflammation: mechanisms and consequences.
Hunt PW
Curr HIV/AIDS Rep; 2012 Jun; 9(2):139-47. PubMed ID: 22528766
[TBL] [Abstract][Full Text] [Related]
10. Associations between serum albumin and serious non-AIDS events among people living with HIV.
Ronit A; Hatleberg CI; Ryom L; Bonnet F; El-Sadr W; Reiss P; Weber R; Pradier C; De Wit S; Law M; d'Arminio Monforte A; Lundgren J; Mocroft A; Phillips AN; Sabin CA;
AIDS; 2018 Aug; 32(13):1837-1848. PubMed ID: 29847331
[TBL] [Abstract][Full Text] [Related]
11. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
12. Serious Non-AIDS Conditions in HIV: Benefit of Early ART.
Lundgren JD; Borges AH; Neaton JD
Curr HIV/AIDS Rep; 2018 Apr; 15(2):162-171. PubMed ID: 29504063
[TBL] [Abstract][Full Text] [Related]
13. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.
Braitstein P; Palepu A; Dieterich D; Benhamou Y; Montaner JS
AIDS; 2004 Nov; 18(17):2221-34. PubMed ID: 15577534
[TBL] [Abstract][Full Text] [Related]
14. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
Wohl DA; Kendall MA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Benson C; Keiser P; van der Horst C; Jacobson MA;
PLoS One; 2013; 8(11):e78676. PubMed ID: 24260125
[TBL] [Abstract][Full Text] [Related]
15. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
[TBL] [Abstract][Full Text] [Related]
16. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.
Antiretroviral Therapy Cohort Collaboration
Clin Infect Dis; 2010 May; 50(10):1387-96. PubMed ID: 20380565
[TBL] [Abstract][Full Text] [Related]
17. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study.
Rasmussen LD; May MT; Kronborg G; Larsen CS; Pedersen C; Gerstoft J; Obel N
Lancet HIV; 2015 Jul; 2(7):e288-98. PubMed ID: 26423253
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of aging in HIV: inflammation and the microbiome.
Tincati C; Merlini E; Ancona G; Marchetti G
Eur Geriatr Med; 2019 Apr; 10(2):175-182. PubMed ID: 34652744
[TBL] [Abstract][Full Text] [Related]
19. Effect of probiotic bacteria on microbial host defense, growth, and immune function in human immunodeficiency virus type-1 infection.
Cunningham-Rundles S; Ahrné S; Johann-Liang R; Abuav R; Dunn-Navarra AM; Grassey C; Bengmark S; Cervia JS
Nutrients; 2011 Dec; 3(12):1042-70. PubMed ID: 22292110
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
